Auriga Upgrades Allscripts-Misys Healthcare (MDRX) to Buy; All Aboard Allscripts (Again!)

Auriga upgraded Allscripts-Misys Healthcare (NASDAQ: MDRX) from Hold to Buy with a price target lowered to $22.00.

Auriga analyst says, "We are upgrading our rating on Allscripts to BUY based on
its depressed valuation relative to the broader health IT group and narrowing of
guidance to the upper end for FY11. Valuation aside, we note that the multiple
reasons that were the foundation for our downgrade in April still persist - namely,
the departure of CTO Gomez, significant attrition by key leaders of both Eclipsys
and legacy Allscripts, and low ratings of the Enterprise ambulatory EMR (formerly
Touchworks) product."

For more ratings news on Allscripts-Misys Healthcare click here and for the rating history of Allscripts-Misys Healthcare click here.

Shares of Allscripts-Misys Healthcare closed at $16.74 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Berenberg Upgrades Mobileye N.V (MBLY) to Buy